Ubrogepant, the oral calcitonin gene-related peptide (CGRP) receptor antagonist from Allergan plc, hit the co-primary efficacy endpoints in ACHIEVE I, the first of two pivotal phase III trials evaluating the candidate to treat acute migraine in adults. Both 50-mg and 100-mg doses showed a statistically significant difference in the percentage of individuals treated with ubrogepant who achieved pain freedom two hours after the initial dose compared to placebo (50 mg vs. placebo, p=0.0023, 100 mg vs. placebo, p=0.0003) – response rates of about 19 percent and 21 percent, respectively, for the treatment arms compared to 12 percent for placebo.